Blood Coagulation Factor Ii Or Factor Ii + Vii + Ix + X, I.e., Prothrombin Complex Or Factor Patents (Class 530/384)
  • Patent number: 10202416
    Abstract: The present invention relates to a method for the purification of divalent cation binding proteins with high purity on an anion exchange resin material, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Grant
    Filed: April 29, 2011
    Date of Patent: February 12, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 9738884
    Abstract: The present invention provides a therapeutic agent for epithelial and endothelial injury, and in particular, for epithelial and endothelial microinjury, and the like. The therapeutic agent according to the present invention comprises, for example, a peptide of the following (a), (b), etc., a derivative thereof, or their salt: (a) a peptide comprising the amino acid sequence shown in any one of SEQ ID NOS: 10, 4, 12 and 6; or (b) a peptide comprising the amino acid sequence shown in any one of SEQ ID NOS: 16, 18, 20 and 22.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: August 22, 2017
    Assignee: NIHON UNIVERSITY
    Inventors: Chiaki Hidai, Hisataka Kitano, Atsushi Mamiya
  • Patent number: 9701710
    Abstract: The present invention relates to a two-step method for the purification of divalent cation binding proteins with high yield and high purity on anion exchange resin materials, to divalent cation binding proteins obtainable by said method, and to a kit comprising means for carrying out said method.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: July 11, 2017
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Patent number: 9347054
    Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is polyethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: May 24, 2016
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson Phillips
  • Patent number: 9023796
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: May 5, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • Publication number: 20150105321
    Abstract: The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 16, 2015
    Inventors: Henrik Oestergaard, Prafull S. Gandhi, Ole Hvilsted Olsen
  • Patent number: 8968725
    Abstract: The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. Also provided is method for repairing tissue defects by administering the gel to site of tissue defect.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: March 3, 2015
    Assignee: University of Vermont and State Agricultural College
    Inventors: Rachel Schek, Arthur J. Michalek, James C. Iatridis
  • Patent number: 8945897
    Abstract: The invention relates to materials and methods of conjugating a water soluble fatty acid derivative to a therapeutic protein comprising contacting the therapeutic protein with an activated water soluble fatty acid derivative under conditions that allow conjugation.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: February 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Richard Sheinecker, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 8889129
    Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: November 18, 2014
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
  • Publication number: 20140335051
    Abstract: The synergistic biomolecule-polymer conjugates are the long-acting, in vivo controlled continuous-release and hybrid synergy systems of biomolecules that provide increased biological activities and enhanced pharmacological properties for achieving greater therapeutic efficacies.
    Type: Application
    Filed: July 28, 2014
    Publication date: November 13, 2014
    Applicant: PEG Biosciences, Inc.
    Inventor: Chyi Lee
  • Publication number: 20140316112
    Abstract: This invention is directed to the use of a chorionic gonadotrophin carboxy terminal peptide (CTP) or fragments thereof for modifying a polypeptide or a fragment thereof in order to increase the hydrodynamic volume of the polypeptide or fragment thereof.
    Type: Application
    Filed: November 20, 2013
    Publication date: October 23, 2014
    Inventors: Oren HERSHKOVITZ, Ahuva BAR-ILAN
  • Patent number: 8865868
    Abstract: The invention relates to conjugated proteins, in particular but not exclusively, blood coagulation factors, to processes for preparing the conjugated proteins which contain the steps of reacting a protein or glycoprotein, such as factor VIIa or human growth hormone, with a water insoluble albumin binder in the presence of an optionally substituted cyclodextrin molecule, to pharmaceutical compositions comprising the protein conjugates and to the use of the protein conjugates in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: October 21, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Carsten Behrens, Patrick William Garibay, Søren Østergaard, Henrik Sune Andersen, Nils Langeland Johansen, Bernd Peschke, Sonja Bak
  • Publication number: 20140303353
    Abstract: The present application relates to methods for purifying recombinant coagulation factor proteins, including for example, prothrombin (Factor II). In embodiments, the methods provide purified prothrombin that exhibit increased bioactivity and reduced levels of thrombin, thereby increasing the safety of the prothrombin. Also provided are purified recombinant coagulation factor proteins.
    Type: Application
    Filed: August 31, 2012
    Publication date: October 9, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Alan Hunter, Xiangyang Wang, Timothy Pabst, Michaela Wendeler, Jihong Wang, Kendall Carey, Robert Strouse, Johnson Varghese
  • Publication number: 20140301974
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Application
    Filed: January 30, 2014
    Publication date: October 9, 2014
    Applicant: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-Wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • Patent number: 8828676
    Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 9, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
  • Patent number: 8815250
    Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: August 26, 2014
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Daniel S. Rivera, Robert T. Peters, Alan J. Bitonti
  • Patent number: 8809016
    Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: August 19, 2014
    Assignee: Regents of the University of Minnesota
    Inventor: Gary L. Nelsestuen
  • Patent number: 8765915
    Abstract: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked by oligonucleotides which code for intervening peptidic linkers such encoded derivatives exhibiting improved stability and extended functional plasma half-life, recombinant expression vectors containing such cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having improved stability and prolonged shelf-life and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.
    Type: Grant
    Filed: February 3, 2007
    Date of Patent: July 1, 2014
    Assignee: CSL Behring GmbH
    Inventors: Thomas Weimer, Stefan Schulte, Ulrich Kronthaler, Wiegand Lang, Uwe Liebing, Wilfried Wormsbächer
  • Patent number: 8759292
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: June 24, 2014
    Assignee: Prolor Biotech, LLC
    Inventors: Udi Eyal Fima, Gili Hart
  • Patent number: 8754062
    Abstract: The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: June 17, 2014
    Assignee: Moderna Therapeutics, Inc.
    Inventors: Antonin de Fougerolles, Kristy M. Wood, Sayda M. Elbashir, Jason P. Schrum
  • Patent number: 8741285
    Abstract: Intra-arterial administering at least one blood coagulation to a bleeding patient is provided, together with a pharmaceutical composition therefor.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: June 3, 2014
    Inventors: Dietmar Fries, Michael Rieger
  • Patent number: 8741845
    Abstract: ClotBlock is a lyophilized fibrin hemostatic designed for use an adjunct or primary treatment in moderate to severe hemorrhage. It can be applied directly to the wound in a laparotomy procedure or as non-invasive sealant. Its crosslinking technology generates a strong and safe adhesive fibrin sealant required for high volume hemostasis. The attachment properties of the cake as well as the rapid formation of and stability of the fibrin clot ensures that a strong stable fibrin clot is formed within 1 to 5 minutes depending on the grade of the wound. The agent is safe, biocompatible, biodegradable and can be stored at room temperature for one year.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: June 3, 2014
    Assignee: Biomedica Mangement Corporation
    Inventors: George David Falus, Leonid Medved
  • Patent number: 8716448
    Abstract: The present invention relates to compositions comprising factor VII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: May 6, 2014
    Assignee: Amunix Operating Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Willem Stemmer, Chia-wei Wang, Benjamin Spink, Nathan Geething, Wayne To
  • Patent number: 8710188
    Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: April 29, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Brian M. Beyer, Alan W. Hruza, Richard N. Ingram, Vincent S. Madison, Andrew J. Prongay, Paul Reichert
  • Patent number: 8697844
    Abstract: The invention relates to a method of purifying PEGylated proteins by removing impurities from samples containing PEGylated proteins, in particular, but not exclusively vitamin K-dependent blood coagulation factors such as Factor IX (FIX), to proteins purified by said method and to the use of said purified proteins in therapy, in particular but not exclusively, for the treatment of diseases alleviated by blood coagulation factors such as the prophylactic treatment of hemophilia.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: April 15, 2014
    Assignee: Novo Nordisk A/S
    Inventors: Matthias Karl Dietrich Wiendahl, Lars Sejersgaard, Are Bogsnes
  • Patent number: 8686225
    Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, as well as to methods of making these isolated blood proteins and to therapeutic compositions comprising them.
    Type: Grant
    Filed: April 17, 2012
    Date of Patent: April 1, 2014
    Assignee: Ventria Bioscience Inc.
    Inventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
  • Patent number: 8679783
    Abstract: A Factor X (hereinafter referred to as “FX”) with a high activity is provided. The present invention relates to a method for efficiently preparing a recombinant, two-chain FX which comprises intervening glycosylation at such an amino acid sequence that is essential for glycosylation in FX to thereby allow for expression of a recombinant FX with no glycosylation, and the recombinant FX with no glycosylation obtained by said method.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: March 25, 2014
    Assignee: The Chemo-Sero-Therapeutic Research Institute
    Inventors: Kenji Soejima, Takayuki Imamura, Ryoichi Kawamura, Hiroshi Nakatake, Arisa Maeyashiki, Hitomi Togo
  • Patent number: 8658597
    Abstract: The invention relates to chemically as well as physically stable kits and compositions comprising polypeptides, in particular Factor VII or Factor VII-related polypeptides, such that these compositions can be stored, handled and used at room temperature.
    Type: Grant
    Filed: March 19, 2009
    Date of Patent: February 25, 2014
    Assignee: Novo Nordisk HealthCare AG
    Inventors: Birthe Lykkegaard Hansen, Michael Bech Jensen, Troels Kornfelt
  • Patent number: 8647868
    Abstract: Methods and cell lines for overexpressing functional gamma-carboxylated proteins are disclosed by way of genetically engineered cell lines which over-express VKORC1. Also disclosed is the antisense inhibition of expression of calumenin in conjunction with overexpression of VKORC1 which also increases expression of functional gamma-carboxylated proteins. Gamma-carboxylated proteins of interest may include blood coagulation factors such as human clotting factors IX and VII.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: February 11, 2014
    Assignee: Wake Forest University Health Sciences
    Inventor: Reidar Wallin
  • Patent number: 8642738
    Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 4, 2014
    Assignee: Regents of the University of Minnesota
    Inventor: Gary L. Nelsestuen
  • Patent number: 8637640
    Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a blood coagulation protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer. In one embodiment of the invention the conjugation is carried out in the presence of the nucleophilic catalyst aniline. In addition the generated oxime linkage can be stabilized by reduction with NaCNBH3 to form an alkoxyamine linkage.
    Type: Grant
    Filed: July 26, 2010
    Date of Patent: January 28, 2014
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
  • Patent number: 8632771
    Abstract: Modifications of vitamin K-dependent polypeptides that lead to enhanced protein function on a weight or molar basis and/or increase of protein lifetime in the circulation are described. Both objectives are important for using vitamin K-dependent polypeptides for pro- and anti-coagulation therapies, as well as for other uses in the circulation.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: January 21, 2014
    Assignees: Regents of the University of Minnesota, The United States of America as represented by Department of Veterens Affairs
    Inventors: Gary L. Nelsestuen, Ronald Bach, Matthew Stone, Stephen Barrett Harvey
  • Patent number: 8633300
    Abstract: The present invention relates to method for selective reduction and derivatization of recombinantly prepared engineered proteins comprising at least one non-native cysteine, wherein the reduction reaction is conducted in the presence of a redox buffer or in the presence of a triarylphosphine reducing agent.
    Type: Grant
    Filed: June 19, 2006
    Date of Patent: January 21, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Henrik Ostergaard, Anders Klarskov Petersen
  • Patent number: 8598319
    Abstract: The invention is related to a process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing freeze-dried concentrates of said proteins comprising the steps of: chromatographic purification comprising the steps of loading an anion exchanger of weak base type with the said solubilized fraction, previously equilibrated with a buffer of a predetermined ionic strength of an alkaline pH, which allows to retain the biological glue, elution of the biological glue by increasing the ionic strength of the said buffer, and separation of FXIII from fibrinogen by addition to at least one part of the biological glue eluate of at least one chemical agent precipitating the FXIII, and recovery of the resulting purified fibrinogen containing supernatant solution, and diafiltration of the fibrinogen, biological glue and resolubilized FXIII solutions, followed by a freeze-drying of said solutions.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: December 3, 2013
    Assignee: Laboratoire Francais du Fractionnement et des Biotechnologies
    Inventors: Nogré Michel, Porte Pierre, Tellier Michel
  • Patent number: 8586711
    Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: November 19, 2013
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson
  • Publication number: 20130296534
    Abstract: Disclosed is a fusion protein comprising blood coagulation factor IX (FIX) and transferrin. The fusion protein exhibits improved specific FIX activity, as compared to native FIX, and can be useful in the treatment of FIX deficiency-associated diseases.
    Type: Application
    Filed: October 19, 2011
    Publication date: November 7, 2013
    Applicant: SK CHEMICALS CO., LTD.
    Inventors: Min Sun Lee, Hun-Taek Kim, Bong-yong Lee, Mahn Hoon Park, Yun Jung Lim
  • Publication number: 20130261060
    Abstract: The present invention relates to chimeric derivatives of serine protease zymogen containing the activation peptide of factor X or a fragment thereof for improving the half-life of said derivatives. Preferably, said chimeric derivatives are protein C and factor X derivatives. The invention also relates to said derivatives for the prevention or treatment of blood coagulation disorders.
    Type: Application
    Filed: June 4, 2013
    Publication date: October 3, 2013
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Olivier Christophe, Cecile Denis, Ghislaine Cherel, Paul Gueguen
  • Patent number: 8536127
    Abstract: Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof is selected from silica-coated glass, silicone-coated glass, polymers of non-cyclic olefins, cycloolefin polymers and cycloolefin/linear olefin copolymers and (ii) one or more closure portions not constituting part of the wall portion, and which contains a formulation of a protein. Also provided are new methods of storing proteinaceous compositions. In one aspect, the stored protein is characterized as having an amino-terminal ?-carboxyglutamic acid (Gla) domain with 9-12 Gla residues.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: September 17, 2013
    Assignee: Novo Nordisk Healthcare AG
    Inventors: Michael Bech Jensen, Birthe Lykkegaard Hansen, Troels Kornfelt, Kirsten Kramer Jakobsen
  • Patent number: 8519103
    Abstract: Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: August 27, 2013
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Edwin L. Madison, Christopher Thanos
  • Patent number: 8513386
    Abstract: The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assay in FVIII-depleted plasma as well as in FVIII-inhibited patient plasma. In FVIII-depleted plasma functional activity of the FIX mutants was calculated as increased FVIII equivalent activity. The mutant proteins had increased FVIII equivalent activity. In FVIII-inhibited patient plasma the FEIBA equivalent activity was calculated for analysis of FVIII independent FX activation potential. The proteins had also increased FEIBA equivalent activity. Furthermore, the pre-activated FIX proteins had an increased activity in FIX-depleted plasma containing FVIII inhibitors.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: August 20, 2013
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger
  • Publication number: 20130195799
    Abstract: The synergistic biomolecule-polymer conjugates are the long-acting, in vivo controlled continuous-release and hybrid synergy systems of biomolecules that provide increased biological activities and enhanced pharmacological properties for achieving greater therapeutic efficacies.
    Type: Application
    Filed: August 19, 2011
    Publication date: August 1, 2013
    Applicant: PEG BIOSCIENCES, INC.
    Inventor: Chyi Lee
  • Publication number: 20130171095
    Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
    Type: Application
    Filed: October 10, 2012
    Publication date: July 4, 2013
    Applicant: Xencor, Inc.
    Inventor: Xencor, Inc.
  • Patent number: 8476234
    Abstract: Polypeptides and polynucleotides encoding same comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a coagulation factor and not to an amino terminus are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: July 2, 2013
    Assignee: Prolor Biotech Inc.
    Inventors: Udi Eyal Fima, Gili Hart
  • Publication number: 20130150557
    Abstract: The present invention relates to a method for the purification of rFIX using anion exchange chromatography in the pseudo-affinity mode, wherein said method comprises a wash step with a wash buffer having a salt concentration of more than 200 mM. The purification according to the invention provides a method to enrich rFIX molecules which have been posttranslationally modified by sulfation and/or phosphorylation. The present invention further relates to purified rFIX compositions enriched in monosulfated and/or monophosphorylated rFIX molecules.
    Type: Application
    Filed: February 12, 2013
    Publication date: June 13, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Baxter International Inc., Baxter Healthcare S.A.
  • Patent number: 8461115
    Abstract: The present invention provides methods for the local treatment of bleeding in a subject and/or reducing unwanted effects associated with the systemic administration of thrombotic agents to a subject, by local administration of FVII to the subject.
    Type: Grant
    Filed: March 16, 2007
    Date of Patent: June 11, 2013
    Assignee: Stellaris Pharmaceuticals ApS
    Inventor: Lars Otto Uttenthal
  • Patent number: 8454833
    Abstract: A method is disclosed for filtering a protein in a liquid mixture in a manner that does not substantially damage or otherwise limit the recovery of the protein in the filtration filtrate. The method generally includes passing a liquid mixture containing a protein (e.g., an aqueous vWF mixture) through a filter while applying a counter pressure to the liquid mixture filtrate to accurately reduce and control the pressure differential across the filter. The disclosed method has the advantage that relatively high filtration flow rates can be achieved at relatively low pressure differentials, in contrast to high pressure differentials, which actually reduce the filtration flow rate of protein liquid mixtures. Further, the method can recover substantially all of the protein that is initially present in the liquid mixture.
    Type: Grant
    Filed: November 16, 2011
    Date of Patent: June 4, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Nebojsa Nikolic, Michaela Frey, Wolfgang Grabmayer, Thomas Jancik, Matthias Fried, Klaus Tschetschkowitsch, Kurt Schnecker, Barbara Riegler, Alma Kasapovic
  • Patent number: 8455439
    Abstract: The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: June 4, 2013
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Genmin Lu, Uma Sinha
  • Publication number: 20130116410
    Abstract: A method for stabilising a human blood protein or human blood plasma protein with a molecular weight of >10 KDa by adding melezitose to a solution comprising the human blood protein or human blood plasma protein with a molecular weight of >10 KDa.
    Type: Application
    Filed: April 20, 2011
    Publication date: May 9, 2013
    Applicant: OCTAPH ARMA AG
    Inventors: Elsa Ivarsson, Josefin Knutsson, Brita Rippner, Ulrika Nilsson, Irene Agerkvist
  • Patent number: 8431535
    Abstract: The present invention provides methods for the local treatment of tracheal, bronchial or alveolar bleeding or hemoptysis and/or reducing unwanted effects associated with systemic administration of thrombotic agents to a subject via intratracheal, intrabronchial or intraalveolar administration of a blood coagulation factor to the subject.
    Type: Grant
    Filed: September 9, 2005
    Date of Patent: April 30, 2013
    Assignee: Hoiberg A/S
    Inventors: Lars Heslet, Lars Otto Uttenthal
  • Patent number: 8415458
    Abstract: The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: April 9, 2013
    Assignee: Regents of the University of Minnesota
    Inventor: Gary L Nelsestuen